Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Cost of Revenue: 2021-2025

Historic Cost of Revenue for BridgeBio Pharma (BBIO) over the last 4 years, with Sep 2025 value amounting to $6.6 million.

  • BridgeBio Pharma's Cost of Revenue rose 997.49% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 524.54%. This contributed to the annual value of $3.9 million for FY2024, which is 58.54% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Cost of Revenue stood at $6.6 million, which was up 79.66% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Cost of Revenue registered a high of $6.6 million during Q3 2025, and its lowest value of $598,000 during Q3 2023.
  • Over the past 3 years, BridgeBio Pharma's median Cost of Revenue value was $599,000 (recorded in 2023), while the average stood at $1.7 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Cost of Revenue slumped by 58.28% in 2022, and later surged by 997.49% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Cost of Revenue (Quarterly) stood at $1.6 million in 2021, then crashed by 58.28% to $647,000 in 2022, then decreased by 7.57% to $598,000 in 2023, then soared by 248.49% to $2.1 million in 2024, then soared by 997.49% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $3.7 million for Q2 2025, and $2.6 million during Q1 2025.